BeiGene Quick Performance Report: Net profit attributable to parent company in 2025 reaches 1.422 billion yuan, turning a profit year-on-year

CryptocurrencySniper · 2026-02-26T12:21:25+00:00

BeiGene's 2025 Performance Brief shows total revenue increased by 40.40% year-over-year to 38.205 billion yuan, with a net profit of 1.422 billion yuan, turning losses into gains. Product revenue rose to 37.770 billion yuan, mainly due to the sales growth of BeiYueZe® and other products.

CryptocurrencySniper

2026-02-26 12:21:25

Abstract generation in progress

BeiGene Announces 2025 Performance Briefing: Total Revenue Reaches 38.205 Billion Yuan, Up 40.40%; Net Profit Attributable to Shareholders of the Listed Company Is 1.422 Billion Yuan, Compared to a Loss of 4.978 Billion Yuan in the Same Period Last Year; Basic Earnings Per Share Is 1 Yuan. In 2025, the company’s product revenue was 37.77 billion yuan, compared to 26.994 billion yuan in the same period last year. The growth in product revenue is mainly due to the sales increase of BeiGene’s Zepzelca® (Zebutinib), as well as authorized products from Amgen and the sales growth of BeiGene’s BeiZan® (Tarellelizumab).

(Source: Jiemian News)

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.